Intarcia slashes headcount after FDA rejects diabetes drug-device combo

Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports.
The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. regulatory agency in September, after the FDA found problems with the manufacturing process used to make ITCA 650.
Get the full story at our sister site, Drug Delivery Business News.
The post Intarcia slashes headcount after FDA rejects diabetes drug-device combo appeared first on MassDevice.

Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Intarcia Therapeutics Source Type: news